Kang, Yubin http://orcid.org/0000-0001-6678-8732
Sundaramoorthy, Pasupathi
Gasparetto, Cristina
Feinberg, Daniel
Fan, Shengjun
Long, Gwynn
Sellars, Emily
Garrett, Anderson
Tuchman, Sascha A.
Reeves, Brandi N.
Li, Zhiguo
Liu, Bei
Ogretmen, Besim
Maines, Lynn
Ben-Yair, Vered Katz
Smith, Charles
Plasse, Terry
Funding for this research was provided by:
US NIH NCI (R44CA199767)
NCI (R01CA197792, R21CA234701)
Article History
Received: 20 May 2022
Accepted: 13 November 2022
First Online: 3 December 2022
Declarations
:
: The study was conducted according to the Declaration of Helsinki and the International Council on Harmonization. The Duke Institutional Review Board (IRB) approved the protocol. All patients provided written informed consent.
: All authors approved the manuscript and the submission.
: Yubin Kang received research funding from InCyte Corporation and a consultancy fee from Takeda Oncology USA and Sanofi Genzyme Corp. Charles Smith is the CEO and President, and Lynn Maines is employed by Apogee Biotechnology Corporation. Vered Katz Ben-Yair and Terry Plasse are consultants to RedHill Biopharma Limited. All other authors declare no competing conflicts of interest.